CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 88 enrolled
Drug / intervention
Recombinant erythropoietin alpha (rHuEPO alpha) +1 moredrug
Likely dose
Recombinant erythropoietin alpha (rHuEPO alpha) 40.000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00425698
NCT00425698Phase 3Completed
CompareCT.gov

Effect of Erythropoietin on Renal Function After Kidney Transplantation

Hannover Medical School·interventional·Posted Jan 23, 2007·Updated Sep 28, 2010

In Brief

A Phase 3 clinical trial evaluating Recombinant erythropoietin alpha (rHuEPO alpha) and Placebo for Kidney Transplantation. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue damage and loss of renal function after successful kidney transplantation in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2007
Enrollment StartFeb 1, 2007
Primary CompletionMay 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.4 years ago

Interventions

Recombinant erythropoietin alpha (rHuEPO alpha)drug

Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

Placebodrug

Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation